<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bagade, Aditi</style></author><author><style face="normal" font="default" size="100%">Nandre, Vinod</style></author><author><style face="normal" font="default" size="100%">Paul, Dhiraj</style></author><author><style face="normal" font="default" size="100%">Patil, Yugendra</style></author><author><style face="normal" font="default" size="100%">Sharma, Nisha</style></author><author><style face="normal" font="default" size="100%">Giri, Ashok</style></author><author><style face="normal" font="default" size="100%">Kodam, Kisan</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Characterisation of hyper tolerant Bacillus firmus L-148 for arsenic oxidation</style></title><secondary-title><style face="normal" font="default" size="100%">Environmental Pollution</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Arsenic hyper-tolerance</style></keyword><keyword><style  face="normal" font="default" size="100%">Lonar lake</style></keyword><keyword><style  face="normal" font="default" size="100%">Microcosm studies</style></keyword><keyword><style  face="normal" font="default" size="100%">Multi-metal resistance</style></keyword><keyword><style  face="normal" font="default" size="100%">Next generation sequencing</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">JUN</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">261</style></volume><pages><style face="normal" font="default" size="100%">114124</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Groundwater arsenic pollution causes millions of deaths worldwide. Long term natural and anthropogenic activities have increased arsenic levels in groundwater causing higher threats of arsenic exposure. Arsenic hyper-tolerant Firmicute Bacillus firmus L-148 was isolated from arsenic limiting Lonar lake soil, which tolerated more than 3 M arsenic and could oxidize 75 mM arsenite [As(III)] in 14 days. It oxidized As(III) in presence of heavy metals and had unusual pH optima at 9.2. B. firmus L-148 was studied at the biochemical, protein, genomic and transcript level for understanding its arsenic oxidizing machinery. The proteomic and transcript analysis exhibited the presence of ars and aio operon and supported the inducible nature of ars operon. Robust, hyper-tolerant, fast As(III) oxidizing, least nutrient requiring and multi-metal resistance qualities of the strain were used in microcosm studies for bioremediation. Artificial groundwater mimicking microcosm with 75 mM As(III) was developed. Modulation of carbon source, iron and multi metals affected growth and As(III) oxidation rate. The As(III) oxidation was recorded to be 77% in 15 days in presence of sodium acetate and Fe ions. This microcosm study can be explored for bioremediation of arsenic contaminated water and followed by precipitation using other methods. (C) 2020 Elsevier Ltd. All rights reserved.&lt;/p&gt;
</style></abstract><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;6.792&lt;/p&gt;
</style></custom4></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bansode, Sneha</style></author><author><style face="normal" font="default" size="100%">Singh, Pawan Kumar</style></author><author><style face="normal" font="default" size="100%">Tellis, Meenakshi</style></author><author><style face="normal" font="default" size="100%">Chugh, Anita</style></author><author><style face="normal" font="default" size="100%">Deshmukh, Narendra</style></author><author><style face="normal" font="default" size="100%">Gupta, Mahesh</style></author><author><style face="normal" font="default" size="100%">Verma, Savita</style></author><author><style face="normal" font="default" size="100%">Giri, Ashok</style></author><author><style face="normal" font="default" size="100%">Kulkarni, Mahesh</style></author><author><style face="normal" font="default" size="100%">Joshi, Rakesh</style></author><author><style face="normal" font="default" size="100%">Chaudhary, Dhruva</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Comprehensive molecular and clinical investigation of approved Anti-HCV drugs repurposing against SARS-CoV-2 infection: a glaring gap between benchside and bedside medicine</style></title><secondary-title><style face="normal" font="default" size="100%">Vaccines</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">antiviral</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">daclatasvir</style></keyword><keyword><style  face="normal" font="default" size="100%">ledipasvir</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style  face="normal" font="default" size="100%">sofosbuvir</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">MAR</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">11</style></volume><pages><style face="normal" font="default" size="100%">515</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;
	The limited availability of effective treatment against SARS-CoV-2 infection is a major challenge in managing COVID-19. This scenario has augmented the need for repurposing anti-virals for COVID-19 mitigation. In this report, the anti-SARS-CoV-2 potential of anti-HCV drugs such as daclatasvir (DCV) or ledipasvir (LDP) in combination with sofosbuvir (SOF) was evaluated. The binding mode and higher affinity of these molecules with RNA-dependent-RNA-polymerase of SARS-CoV-2 were apparent by computational analysis. In vitro anti-SARS-CoV-2 activity depicted that SOF/DCV and SOF/LDP combination has IC50 of 1.8 and 2.0 mu M, respectively, comparable to remdesivir, an approved drug for COVID-19. Furthermore, the clinical trial was conducted in 183 mild COVID-19 patients for 14 days to check the efficacy and safety of SOF/DCV and SOF/LDP compared to standard of care (SOC) in a parallel-group, hybrid, individually randomized, controlled clinical study. The primary outcomes of the study suggested no significant difference in negativity after 3, 7 and 14 days in both treatments. None of the patients displayed any worsening in the disease severity, and no mortality was observed in the study. Although, the post hoc exploratory analysis indicated significant normalization of the pulse rate showed in SOF/DCV and SOF/LDP treatment vs. SOC. The current study highlights the limitations of bench side models in predicting the clinical efficacy of drugs that are planned for repurposing.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;
	Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;
	4.961&lt;/p&gt;
</style></custom4></record></records></xml>